Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Savolitinib + Osimertinib vs Pemetrexed + Platinum in NSCLC with MET Amplification
NCT05015608Phase 3Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Nov 2021
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of savolitinib in non-small cell lung cancer (NSCLC), sponsored by Hutchison MediPharma (HMP). Started Nov 2021; status: completed.
02
Drugs
savolitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05015608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05015608.